Humanin vs SS-31
Research Verdict
SS-31 is the stronger research reference for the stated comparison criteria. Elamipretide has accelerated FDA approval for Barth syndrome; humanin remains preclinical.
Quick Answers
Which is better, Humanin or SS-31?
SS-31 is the stronger research reference for the stated comparison criteria. Elamipretide has accelerated FDA approval for Barth syndrome; humanin remains preclinical.
What is the key difference between Humanin and SS-31?
SS-31 targets cardiolipin on the inner mitochondrial membrane for energy production; humanin targets BAX-mediated apoptosis for cell survival - both are mitochondria-related but address different aspects of mitochondrial dysfunction.
Evidence Comparison
Elamipretide has accelerated FDA approval based on a small Barth-syndrome program; its randomized primary endpoints were negative. Humanin has independent preclinical neuroprotection research but no human efficacy trial. Elamipretide has the stronger clinical and regulatory evidence.
Evidence Context Favoring Humanin
Neuroprotection and apoptosis research where the BAX inhibition mechanism is the research question.
Evidence Context Favoring SS-31
Barth syndrome or cardiolipin-targeted mitochondrial research; heart-failure efficacy remains unestablished.
Side-by-Side Snapshot
| Evidence grade | Humanin: Level D SS-31: Level B |
|---|---|
| Research status | Humanin: Preclinical SS-31: FDA Approved |
| Primary category | Humanin: Anti-Aging & Longevity SS-31: Anti-Aging & Longevity |
| Cited studies | Humanin: 3 SS-31: 6 |